Leukemia & Lymphoma Society

Louis DeGennaro named president, CEO of Leukemia & Lymphoma Society

Thursday, September 11, 2014 03:33 PM

The Leukemia & Lymphoma Society (LLS) has appointed Louis J. DeGennaro, Ph.D., president and CEO, effective immediately.

More... »


Leukemia & Lymphoma Society awards $12.6 million in research grants

Wednesday, January 8, 2014 01:24 PM

The Leukemia & Lymphoma Society (LLS), a voluntary health agency dedicated to blood cancer, has awarded 21 new grants representing a total investment of $12.6 million to tackle six areas of high unmet medical need in the blood cancers.

More... »


Evotec collaborates with Leukemia & Lymphoma Society

Wednesday, November 6, 2013 12:59 PM

Evotec has entered into an integrated research collaboration with the Leukemia & Lymphoma Society (LLS). Evotec will support one of LLS's Screen-to-Lead Programs (SLP).

More... »

Stemline Therapeutics, Leukemia & Lymphoma Society collaborate

Wednesday, October 30, 2013 11:14 AM

Stemline Therapeutics, a clinical-stage biopharmaceutical company developing novel oncology therapeutics, and The Leukemia & Lymphoma Society (LLS) are collaborating to accelerate the development of SL-401 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematological disorder with both leukemic and lymphomatous characteristics.

More... »

LLS, Dana-Farber partner to bring clinical trials to local communities

Friday, June 7, 2013 01:29 PM

The Leukemia & Lymphoma Society (LLS), a global voluntary health agency, joined the Dana-Farber Cancer Institute in Boston to establish a network of sites for clinical trial testing of blood cancer therapies in community oncology settings across the country.

More... »

LLS, Valor Biotherapeutics partner to advance novel therapy

Thursday, May 30, 2013 04:18 PM

The Leukemia & Lymphoma Society (LLS), a global voluntary health agency,  is committing approximately $6 million to Valor Biotherapeutics, a joint venture of biotechnology companies ImmunGene and Caliber, to co-fund the completion of preclinical development, manufacturing and a phase I clinical trial for a novel fusion protein that may change the poor outcomes faced by many patients with indolent lymphomas who do not respond to standard therapy with rituximab.

More... »

Leukemia & Lymphoma Society expands chief policy, advocacy officer role

Friday, March 8, 2013 10:34 AM

The Leukemia & Lymphoma Society (LLS) has expanded the role of chief policy and advocacy officer Mark Velleca, M.D., Ph.D. Velleca, who has headed LLS' Office of Public Policy in Washington, D.C., since early 2012, will now oversee the newly integrated patient advocacy, policy and programs department.

More... »

Constellation, LLS to develop novel BET inhibitor for hematologic malignancies

Friday, September 21, 2012 01:12 PM

Constellation Pharmaceuticals, a Cambridge, Mass.-based biopharmaceutical company in the field of epigenetics, has entered into a strategic partnership with the Leukemia & Lymphoma Society (LLS) to advance the development of a novel BET inhibitor for the treatment of patients with hematologic malignancies.

More... »

Leukemia & Lymphoma Society awards $12M in grants for blood cancer

Thursday, August 30, 2012 11:54 AM

The Leukemia & Lymphoma Society (LLS) of White Plains, N.Y., has awarded 20 grants representing a total investment of $12 million to tackle four areas of high unmet medical need in the blood cancers.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs